# Kent Academic Repository

## Full text document (pdf)

### **Citation for published version**

Giotis, Efstathios S. and Carnell, George and Young, Erik F. and Ghanny, Saleena and Soteropoulos, Patricia and Wang, Lin-Fa and Barclay, Wendy S. and Skinner, Michael A. and Temperton, Nigel (2019) Entry of the bat influenza H17N10 virus into mammalian cells is enabled by the MHC class II HLA-DR receptor. Nature Microbiology . ISSN 2058-5276.

## DOI

https://doi.org/10.1038/s41564-019-0517-3

## Link to record in KAR

https://kar.kent.ac.uk/75627/

## **Document Version**

Author's Accepted Manuscript

#### Copyright & reuse

Content in the Kent Academic Repository is made available for research purposes. Unless otherwise stated all content is protected by copyright and in the absence of an open licence (eg Creative Commons), permissions for further reuse of content should be sought from the publisher, author or other copyright holder.

#### Versions of research

The version in the Kent Academic Repository may differ from the final published version. Users are advised to check http://kar.kent.ac.uk for the status of the paper. Users should always cite the published version of record.

#### Enquiries

For any further enquiries regarding the licence status of this document, please contact: **researchsupport@kent.ac.uk** 

If you believe this document infringes copyright then please contact the KAR admin team with the take-down information provided at http://kar.kent.ac.uk/contact.html





1	Entry of the bat influenza H17N10 virus into mammalian cells is enabled by the MHC
2	class-II HLA-DR receptor
3	Efstathios S Giotis <sup>1*</sup> , George Carnell <sup>2 †</sup> , Erik F. Young <sup>3 ††</sup> , Saleena Ghanny <sup>3 †††</sup> , Patricia
4	Soteropoulos <sup>3 +++</sup> , Lin-Fa Wang <sup>4</sup> , Wendy S Barclay <sup>1</sup> , Michael A Skinner <sup>1</sup> , Nigel
5	Temperton <sup>2</sup>
6	<sup>1</sup> Section of Virology, Department of Medicine, St Mary's Campus, Imperial College London, UK.
7	<sup>2</sup> Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent and University of
8	Greenwich, Chatham Maritime, UK.
9	<sup>3</sup> Hackensack University Medical Center Department of Surgery, Hackensack, NJ.
10 11	<sup>4</sup> Programme in Emerging Infectious Disease, Duke-NUS Medical School, Singapore
12	Current affiliations:
13	<sup>†</sup> Laboratory of Viral Zoonotics, Department of Veterinary Medicine, University of Cambridge,
14	UK.
15	<sup>++</sup> Bioelectronic Systems Lab, Columbia University, NY, USA.
16	<sup>+++</sup> Rutgers University, New Jersey Medical School Genomics Center, Newark, NJ, USA.
17	
18	*Corresponding author: Efstathios S Giotis, e.giotis@imperial.ac.uk
19	
20	Abstract
21	Haemagglutinin (HA) and neuraminidase (NA) surface glycoproteins of bat influenza H17N10
22	virus neither bind nor cleave sialic acid receptors, indicating this virus employs cell-entry
23	mechanisms distinct from those of classical influenza A viruses. We observed that certain
24	human haematopoietic cancer cell lines and the canine MDCK II cells are susceptible to H17-
25	pseudotyped viruses. We identified the human HLA-DR receptor as an entry-mediator for

H17-pseudotypes, suggesting that H17N10 possesses zoonotic potential. 26

#### 27 **Main**

Bats are reservoirs of diverse, potentially zoonotic viruses (*e.g. Paramyxoviridae*, *Coronaviridae*, *Filoviridae*), further exemplified by the discovery of the evolutionarily distinct,
influenza A-like viruses H17N10 and H18N11 (BatIVs) in asymptomatic bats<sup>1,2</sup>. This discovery
led to concern that bats may be neglected reservoirs of influenza viruses<sup>3</sup>.

32 The natural reservoir of classical influenza A viruses (IAVs) is aquatic birds, from which they 33 emerge, *via* genome reassortment and mutation, to cause sporadic pandemics in humans and 34 other hosts<sup>4</sup>. The initial cross-species barrier is host cell attachment. The HA mediates virus 35 binding to host-specific sialic acid (SA) moieties<sup>4</sup>. The crystal structures of BatIV HAs exhibit 36 divergence of their protein conformations from those of IAVs and inability to accommodate 37 SA<sup>2,5,6</sup>. Initial efforts to isolate infectious BatIVs from bats failed, mainly because their receptors were unknown<sup>1,2,5,7,8</sup>. Synthetic BatIVs were able to infect mammalian cell lines<sup>9-11</sup>. 38 39 Identifying the BatIV receptors is key to assessing their zoonotic risk.

40

41 Lentivirus-derived pseudotypes (PV) with heterologous envelope proteins have facilitated 42 identification of viral receptors<sup>12</sup> and are valuable in assessing H17N10 tropism<sup>12,13</sup>. We have shown that transduction-competent H17- and H17N10-PV are recovered from HEK293T/17 43 cells only in the presence of proteases (HAT or TMPRSS2) (Fig. 1a)<sup>13</sup>, in keeping with 44 45 published data<sup>11</sup>. To study the distribution of the H17N10 receptor(s), a panel of cell lines 46 (Supplementary Table 1) was challenged with H17-PV, assaying transduction via the 47 expression of PV-encoded luciferase reporter. PV bearing H5 (H5-PV) or VSV-G (VSV-G-PV) 48 served as positive controls; PV without envelope protein ( $\Delta$ -env) as negative. H17-PV 49 displayed highly limited species/cell tropism, in agreement with previous work<sup>9-11</sup>, suggesting 50 the receptor(s) are not ubiquitous (Fig. 1b). Canine MDCK II (unlike MDCK I) cells are 51 susceptible to H17-PV (Fig. 1c) in agreement with previous studies<sup>10,11</sup>. MDCK II cells were 52 not susceptible to PV expressing N10 alone while particles bearing H17 alone or both H17 and N10 transduced these cells with high, comparable efficiency, indicating that N10 is dispensable for entry, in keeping with published data<sup>9,11</sup>. To characterise the H17 putative receptor(s), MDCK II cells were (pre)-treated with enzymatic agents before transduction (Fig. 1d). Pre-treatment with neuraminidase, which cleaves surface SA, reduced transduction by H5-PV (by 68-86%) but not H17-PV, further supporting the notion that SA are not the H17receptors<sup>8-11</sup>.

59

IAVs primarily enter cells via endocytosis followed by low pH-triggered endosomal fusion. Treatment of cells with ammonium chloride blocked uptake of H5- and H17-PV, demonstrating that entry of H17, like IAVs, is pH-dependent consistent with a previous study<sup>9</sup>. Entry of H17-PV was more affected than H5-PV by pre-treatment of cells with proteases or an inhibitor of *N*-glycosylation (reduced by up to 72 and 78%, compared to 45 and 20%, respectively), supporting the supposition<sup>9</sup> that the H17-receptor(s) is a glycoprotein.

67

68 MDCK cells are heterogeneous, displaying phenotypic variation<sup>14</sup>, with MDCK I and II 69 representing early and late passages of the parental NBL-2 cells. Transcriptional differences 70 between early (passage 8) and late (passage 21) MDCKs were investigated using microarrays, 71 identifying 17 differentially regulated transcripts (Fig. 2a). Using transmembrane domain and 72 subcellular localisation prediction algorithms, we identified the dog leukocyte antigen DR $\alpha$ -73 chain (DLA-DRA) as the only transcript encoding a surface-anchored protein, over-expressed 74 in late, compared to early, passage cells (Supplementary Table 2). Significant over-expression 75 of DLA-DRA (and paralogue DLA-DRB1) was confirmed by qRT-PCR in MDCK II compared to I 76 cells (Fig. 2b).

DLA-DRA is a well-conserved orthologue of the human MHC-II HLA-DRA (Supplementary
Figure 1). MHC-II molecules are heterodimers of two glycosylated, transmembrane
polypeptide chains (monomorphic α and polymorphic β), expressed selectively on antigen
presenting cells (APCs; Fig. 2c). HLA-DR forms complexes, with endocytosed foreign
peptides, which are presented to CD4+ T-helper cells for recognition<sup>15</sup>.

83 To assess the zoonotic potential of H17N10, we explored the H17-PV tropism using human 84 cell lines with known elevated HLA-DR expression levels<sup>15</sup> (Fig. 2d). Burkitt's lymphoma-85 derived Raji, Ramos and BIAB B-lymphocytes and the B-lymphoblastoid cells (B-LCL) show 86 decreasing susceptibility, in that order, to H17-PV. Kasumi-1 leukaemic cells showed marginal 87 susceptibility, while Molt-4 and HL-60 leukaemic cells, Jurkat T-cells, pro-monocytic THP-1 88 and U-937, and primary B-cells showed no susceptibility to H17-PV. Differential susceptibility 89 to H17-PV correlated with HLA-DRA expression levels (confirmed by qRT-PCR). Surface 90 expression of the heterodimer was assayed by flow cytometry (Fig. 2e)<sup>16</sup> and showed an 91 association with susceptibility to H17-PV.

92

93 We investigated whether ectopic expression of HLA-DR was sufficient to render non-APC 94 susceptible to H17-PV. HEK293T/17 cells were transiently co-transfected with the DRA and 95 DRB1 expression vectors. Surface expression of the heterodimer was confirmed via 96 immunofluorescence (Supplementary Figure 2). Flow cytometry confirmed 47% of cells 97 formed a functional surface heterodimer (Fig. 2f). Over-expression of HLA-DR resulted in 98 significant transduction by H17-PV. Furthermore, transduction was enhanced two-fold (Fig. 99 2g) in cells FACS-enriched for HLA-DR. Similar results were obtained using bat cells 100 (Supplementary Figure 3). Conversely, small interfering RNA targeting HLA-DRA (Fig. 2h) or 101 MHC-II monoclonal antibodies (Fig. 2i; Supplementary Figure 4) drastically reduced Raji cells' 102 susceptibility to H17-PV.

Together, these findings demonstrate HLA-DR functions as a *bona fide* entry mediator for
H17N10. Similarly, Karakus *et al* determined that bat, pig, mouse or chicken HLA-DR
orthologues mediate cell entry of H18N11<sup>17</sup>. Through efficient binding to HLA-DR, BatIVs
might simultaneously access APCs and block T-cell responses. This might explain the viruses'
survival and asymptomatic status in carrier bats.

With limited functional information available on bat MHC-II, its role in the pathogenesis and transmission of BatIVs remains obscure. Nevertheless, the observation that H17N10 can enter human HLA-DR<sup>+</sup> cells implies that the virus has zoonotic potential.

112

#### 113 Methods

#### 114 **Cell culture and treatment**

115 Cell lines are described in Supplementary Table 1 and were cultured according to standard 116 protocols (www.atcc.org). Bat cell lines were propagated in DMEM supplemented with heat-117 inactivated 15% fetal bovine serum (Life Technologies), penicillin (100 U/ml) and 118 streptomycin (100  $\mu$ g/ml; Invitrogen) and maintained at 37°C and 5% CO<sub>2</sub>.

MDCK II cells were treated as previously<sup>9</sup> with either the endosomal acidification reagent 119 ammonium chloride (1-100 mM), or pre-treated with neuraminidase from *Clostridium* 120 121 perfrigens for 2 h (1-100)mM) or pronase for 30 min (endo-122 and exoproteases from *Streptomyces griseus* at 5-50 µg/ml; Calbiochem), or an N-123 glycosylation inhibitor for 5 h (tunicamycin at 0.01-1  $\mu$ g/ml; Sigma-Aldrich). For experiments 124 using glycosidases, Raji and Ramos cells were treated as previously<sup>18</sup> with 0-100 U/ml 125 Peptide: *N*-glycosidase F (PNGase F; Calbiochem) or endoglycosidase H (endo H; New England 126 Biolabs) or a mixture of neuraminidase (50 mM) and O-glycosidase (1-20 mU/ml) in Hank's 127 Balanced Salt Solution (HBSS; Sigma) for 2 h at 37°C. Cells were washed twice with HBSS and 128 transduced with H17- and VSV-G-PV for 2 h. The cells were then resuspended in fresh growth 129 medium for 24-48 h before assay. Bafilomycin A1 (Calbiochem) was used at a concentration

130 of 10 nM. Cell viabilities were assessed by a trypan blue exclusion test.

131

#### 132 **Pseudotype production and susceptibility assays**

133 Pseudotypes expressing H17 and N10 (from A/little vellow-shouldered 134 bat/Guatemala/060/2011), H5 (A/Vietnam/1194/2004; H5N1 clade 1) or VSV (Vesicular 135 Stomatitis Virus)-G glycoproteins were produced as described<sup>13</sup>. Briefly, the lentiviral 136 packaging plasmid p8.91, the pCSFLW firefly luciferase vector, the pI.18 expression plasmids 137 for H17 and/or N10 and the protease encoding plasmid pCAGGS-HAT were co-transfected 138 using polyethylenimine (PEI) reagent (Sigma-Aldrich) into HEK293T/17 cells. Filtered 139 supernatants were collected 48-72 h post transfection. To remove viral titer bias between 140 different stocks, PV were concentrated and (re-) titrated by serial dilution. Concentration was 141 carried out by ultra-centrifugation for 2 h at 25,000 rpm at 4°C (Beckman Optima XL-100 K 142 Ultracentrifuge).

Two-fold serial dilutions of PV-containing supernatant were performed as previously described<sup>13</sup> using 96-well plates. Subsequently,  $1x10^4$  (for adherent) and  $3x10^4$  cells (for suspension) cells were added in 50 µl of medium per well. Plates were incubated for 24-48 h, after which 50 µl of Bright-Glo<sup>TM</sup> substrate (Promega) was added. Luciferase readings were conducted with a luminometer (FLUOstar OPTIMA, BMG Labtech) after a 5-min incubation. Data was normalized using  $\Delta$ -env and cell-only measurements and expressed as Relative Luminescence Units (RLU)/ml.

150

#### 151 Plasmids and transfections

Expression plasmids for HLA-DRA (NM\_019111) and HLA-DRB1 (NM\_001243965) were purchased from GenScript. HEK293T/17 at sub-confluence in 6-well plates or 100 mm dishes were transfected with HLA-DRA or HLA-DRB1 plasmids or a 1:1 combination of both using Lipofectamine 3000 (Thermo Fisher). 48 h after transfection, cells were used either for immunofluorescence analysis, for FACS analysis or for PV-transduction. The transfection efficiency, as assessed by the GFP expression of a control plasmid, was >70% under microscopic observation. PakiTO3 cells were transfected with HLA-DR plasmids and selected with geneticin (500 µg/ml).

160

#### 161 Microarray analysis

162Total RNA was isolated from triplicates of early and late passage MDCK cells using a Ribopure163kit (Ambion). Preparation of samples and hybridization to Affymetrix Canine Genome 2.0164GeneChips was performed according to standard Affymetrix protocols. A one-way ANOVA165adjusted with the Benjamini–Hochberg multiple-testing correction (p<0.05) was performed</td>166with Partek Genomics Suite (v6.6) as previously described<sup>19</sup>.

167

#### 168 HLA-DRA knockdown and blocking using siRNA and monoclonal antibodies

A Sigma-Aldrich MISSION endonuclease-derived esiRNA (EHU226621) was used to knock down HLA-DRA expression in Raji cells. Lipofectamine RNAiMAX reagent (Thermo Fisher) was used to transfect exponentially grown cells with 50 nM of siHLA-DRA or of siControl (SIC001). Initial transfection was followed by re-transfection of cells on the following day. Cells were collected after 48 h and either seeded for transduction with PV or processed in order to validate siRNA activity (by qRT-PCR and western blot).

To evaluate the interaction of HLA-DR with H17, we used the broadly reactive MHC-II mAb
WR18 (Biorad; code MCA477) and anti-HLA-DR mAb (clone 302CT2, Enzo Life Sciences).
After 1 h pre-incubation with increasing mAb concentrations of the antibody, Raji cells
(3x10<sup>4</sup>) were transduced for 2 h with H17-or VSV-G-PV. The cells were then resuspended in
fresh growth medium and luciferase was measured after 24 h.

#### 181 Western blot analysis

182 Washed cells were lysed on ice with lysis buffer [0.5% NP40 in PBS with 10 mM Tris-HCl, pH 183 7.4 supplemented with protease inhibitors (Thermo Fisher)] and protein was quantified by the BCA assay kit (Thermo Fisher). 20-50 µg of protein was electrophoresed on a 4-15% 184 185 sodium dodecylsulfate polyacrylamide gel, alongside a protein ladder (Bio-Rad) and 186 immunoblotted with the mouse mAb anti-HLA-DRA (1:1000; clone: 302CT2, Enzo Life 187 Sciences) or rabbit mAb a-tubulin (1:2000; Cell signalling Technology). The membranes were 188 washed and incubated with goat anti-rabbit or donkey anti-mouse secondary antibodies (LI-189 COR) in the dark for 1 h. Scanning was carried out using the Odyssey Imaging system.

190

#### 191 Immunofluorescence

192 Transfected cells were seeded onto glass cover slips overnight and were fixed with 4% 193 paraformaldehyde. Fixed cells were then washed and permeabilised with 1% Triton X-100 in 194 PBS for 10 minutes. After washing, the cover slips were incubated with a mouse HLA-DRA 195 mAb (169-1B5.2; Bio-Techne) targeting a monomorphic HLA-DR framework determinant for 196 1 hr, washed and incubated with anti-mouse Alexafluor488 conjugated-Ab (Thermo Fisher) 197 for 30 minutes. Cover slips were mounted using Prolong Gold containing DAPI (Invitrogen). 198 Images were acquired on EVOS fluorescent microscope (Life Technology). Experiments were 199 carried out in duplicate.

200

#### 201 Flow cytometry

For surface staining, cells were washed twice in ice-cold FACS buffer and stained with a FITCconjugated anti-human HLA-DR mAb (clone Tü36; BDIS), which binds to a monomorphic epitope of the  $\alpha\beta$  complex and not the isolated  $\alpha$  or  $\beta$  chains or the HLA-DP and -DQ isotypes<sup>16</sup>. The BD LSR Fortressa was used to determine expression of HLA-DR, in combination with the matched isotype control and cells were sorted into HLA-DR<sup>-</sup> and HLA-

207 DR<sup>+</sup> subpopulations with a FACS Aria cell sorter (BDIS). The Hoechst 33342 stain was used for 208 cell viability discrimination and the data files were analyzed using FlowJo software v10.0 209 (Tree Star, Inc.). Experiments were carried out in duplicate. Gating strategy: cells were first 210 identified by forward (FSC-Area) versus side scatter (SSC-Area) gating based on cell size and 211 granularity, then the FSC-Area vs FSC-Height gating for single cells. Dead cells were excluded 212 by gating on Hoechst 3342 negative cells. Positive and negative gates for HLA-DR expression 213 were determined by using isotype and unstained controls.

214

#### 215 **qRT-PCR analysis**

216 qRT-PCR was performed using procedures described previously<sup>19</sup>. qRT-PCR was conducted in 217 a 384-well plate with the ABI-7900HT system (Applied Biosystems). The following primers 218 were used: DLA-DRA (Forward: 5'-GCTGTGGACAAAGCTAACCTTG-3', Reverse: 5'-219 TCTGGAGGTACATTGGTGTTCG-3'), DLA-DRB1 (Forward: 5'-AGCACCAAGTTTGACAAGC-3', 220 Reverse: 5-AAGAGCAGACCCAGGACAAAG-3'). Absolute copy numbers of HLA-DRA were 221 calculated using a standard curve of known concentrations of the corresponding expression 222 plasmid. HLA-DRA (Forward: 5'-TCAAGGGATTGCGCAAAAGC-3', Reverse: 5'-223 ACACCATCACCTCCATGTGC-3').

224

#### 225 **Bioinformatic and statistical analyses**

Phobius<sup>20</sup> and TMHMM v2.0<sup>21</sup> software were used to predict the existence of transmembrane domains and Deeploc- $1.0^{22}$  was used to determine sub-cellular protein localisation. The amino acid sequences of DLA-DRA (NP\_001011723.1), HLA-DRA (NP\_061984.2), and their bat orthologues [(*Pteropus alecto* (XP\_006907484.1); *Desmodus rotundus* (XP\_024413747.1)] were subjected to multiple alignment using CLC workbench 7. Graphical representation and statistical analyses were performed using Prism 8 (GraphPad). Unless otherwise stated, results are shown as means ± SEM from three independent experiments. Selection of

233	statistical analysis was based on the data distribution. Data distributions were tested
234	for normality using the Shapiro–Wilk normality test. $p$ <0.05 was considered significant unless
235	otherwise stated.
236	
237	Ethics statement: The buffy coat residues for the isolation of CD19 <sup>+</sup> primary B-cells were
238	purchased from the UK Blood Transfusion Service from anonymous volunteer blood donors.
239	Therefore, no ethical approval is required.
240	
241	Competing Interests
242	The authors declare no competing interests.
243	
244	Data Accessibility
245	Microarray data are available at the GEO repository under series record number GSE14837.
246	All other data supporting the findings of this study are available from the authors on
247	request.
248	
249	References:
250 251 252 253 254 255 256 257 258 259 260 261 262 263	<ol> <li>Tong, S. et al. Proc. Natl Acad. Sci. USA 109, 4269-4274 (2012).</li> <li>Tong, S. et al. PLoS Pathog 9, e1003657 (2013).</li> <li>Ciminski, K. et al. J. Gen. Virol. 98, 2393-2400 (2017).</li> <li>Long, J. S. et al. Nat. Rev. Microbiol. (2018).</li> <li>Sun, X. et al. Cell Rep. 3, 769-778 (2013).</li> <li>Zhu, X. et al. Proc. Natl Acad. Sci. U S A 109, 18903-18908 (2012).</li> <li>Juozapaitis, M. et al. Nat. Commun. 5, 4448 (2014).</li> <li>Wu, Y. et al. Trends Microbiol. 22, 183-191 (2014).</li> <li>Maruyama, J. et al. Virology 488, 43-50 (2016).</li> <li>Moreira, E. A. et al. Proc. Natl Acad. Sci. USA 113, 12797-12802 (2016).</li> <li>Hoffmann, M. et al. PLoS ONE 11, e0152134 (2016).</li> <li>Carnell, G. W. et al. Front. Immunol. 6, 161 (2015).</li> <li>Carnell, G. et al. Biorxiv, doi:http://dx.doi.org/10.1101/499947. (2018).</li> </ol>
264 265	14. Dukes, J. D. <i>et al. BMC Cell Biol.</i> <b>12</b> , 43 (2011). 15. Roche, P. A. <i>et al. Nat. Rev. Immunol.</i> <b>15</b> , 203-216 (2015). 16. Ziegler, A. <i>et al. Immunobiology</i> <b>171</b> , 77-92 (1986).

- 267 18. de Vries, E. *et al. Proc. Natl Acad. Sci. USA* **109**, 7457-7462 (2012).
- 268 19. Giotis, E. S. et al. Sci. Rep. 7, 17485 (2017).
- 269 20. Kall, L. *et al. Nucleic Acids Res.* **35**, W429-432 (2007).
- 270 21. Krogh, A. *et al. J. Mol. Biol.* **305**, 567-580 (2001).
- 271 22. Almagro-Armenteros, J. J. *et al. Bioinformatics* **33**, 4049 (2017).
- 272
- 273
- 274

#### 275 Figure Legends

**Figure 1: a.** PV-production schematic. **b.** H17-PV transduction efficiencies in cell lines (*n*=6).

277 Relative Luminescence Units (RLU)/ml are plotted as box-plots (Upper/lower bounds: 25%

and 75% quantiles; middle band: median; whiskers: minimum-maximum values). c. PV-

279 transduction efficiencies (means  $\pm$  SEM, n=8) in MDCK II cells. Statistical significance was

280 determined by Kruscal-Wallis and Dunn's *post-hoc* tests. **d.** Left Y-axis: % PV-transduction

efficiencies in (pre-)treated MDCK II cells (means  $\pm$  SEM, *n*=4). Right Y-axis: % cell viability (means  $\pm$  SEM, *n*=3).


Figure 2: a. Up-/down-regulated (green/red) transcripts identified by microarrays in late-283 284 versus early-passaged MDCKs. Red box: membrane protein-encoded transcript. b. mRNA 285 expression levels (means  $\pm$  SEM, n=4) of DLA-DRA/-DRB1. Significance was calculated by one-way ANOVA and Tukey's tests (\*\*\*p=0.0006; \*\*\*\*p<0.0001). **c.** HLA-DR schematic 286 287 (Motifolio). **d.** Left Y-axis: H17-PV transduction efficiencies in human cell lines [*n*=4; box-plot 288 (top/bottom: min/max values; middle band: median)]. Right Y-axis (line): HLA-DRA mRNA 289 copies (n=4). e. FACS analysis of HLA-DR cell surface expression (representative of two 290 independent experiments). Blue and red peaks represent HLA-DR<sup>-</sup> and -DR<sup>+</sup> subpopulations. f. 291 FACS analysis of HLA-DR expression in HEK293T/17 cells transfected with HLA-DR $\alpha\beta$ 292 plasmids (n=2). Right top corner: immunofluorescence confirming HLA-DR expression (n=2; 293 Scale bar=10  $\mu$ m). g. PV-transduction efficiencies (means ± SEM, n=4) in FACS-sorted DR. 294 unsorted (DR<sup>+</sup> & DR<sup>-</sup>) and FACS-sorted DR<sup>+</sup> HEK293T/17 cells. Significance was calculated by 295 one-way ANOVA and Tukey's tests (\*\*\*\*p<0.0001). h. Left: PV-transduction efficiencies 296 (means  $\pm$  SD, n=3) in Raji cells transfected with siControl or siHLA-DRA. Significance was


297	calculated with a <i>t</i> -test (Holm-Sidak-adjusted) and right: corresponding western blot and
298	qRT-PCR data showing HLA-DRA protein and mRNA levels (means $\pm$ SD, $n=3$ ). qRT-PCR
299	significance was calculated by two-sided <i>t</i> -test ( $p$ =0.0065). i. % PV-transduction levels
300	(means $\pm$ SD, $n=3$ ) in Raji cells pre-incubated with MHC-II monoclonal antibody. Significance
301	was calculated by one-way ANOVA and Dunnett's tests (*** $p$ =0.0003, **** $p$ <0.0001).
302	
303	Corresponding author
304	Correspondence and requests for materials to Efstathios S Giotis
305	
306	Acknowledgements:
307	Our thanks go to Jim Kaufman, Yanping Guo, Ibrahim Elbusifi, Daragh Quinn, Alfred Ho, Kevin
308	Ciminski and Martin Schwemmle for their support. Cells were kindly provided by Dr Edward
309	Wright (University of Sussex, UK), Dr Konstantinos Paschos, Dr Rob White, Dr Marcus Dorner,
310	Dr Michael Edwards, Professor Paul Farrell and Professor Robin Shattock (Imperial College
311	London). This research was undertaken with the financial support of the Biotechnology and
312	Biological Sciences Research Council (BBSRC) (http://www.bbsrc.ac.uk) via Strategic LoLa
313	grant BB/K002465/1 "Developing Rapid Responses to Emerging Virus Infections of Poultry
314	(DRREVIP)" and the Octoberwoman Foundation. L-FW is supported by the Singapore National
315	Research Foundation grants (NRF2012NRF-CRP001-056 and NRF2016NRF-NSFC002-013).
316	
317	Author Contributions: ESG conceived, designed and performed the experiments, analysed
318	data and wrote the manuscript. GC generated luciferase reporter plasmids, produced
319	pseudotype viral stocks and wrote the manuscript. EFY, SG and PS performed microarray


work. WSB, MAS, and NT designed experiments and wrote the manuscript. L-FW provided


321 materials and engaged in discussion of the project.

320














b
















siControl siHLA-DRA





siControl siHLA-DRA

